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Cervical screening is not available for the majority of women in resource-poor countries. An important factor is a lack of skilled
operators necessary for high-throughput assessment of the Papanicolaou (Pap) test currently in use. We compared the efficacy of
immunocytochemistry for minichromosome maintenance (MCM) proteins vs standard Pap testing at detecting disease in 455 cervical
smears processed in a typical Indian screening laboratory. Conventional (non-monolayer) smears were stained manually and then
examined by a cytotechnologist and a cytopathologist. The MCM test was called positive when immunolabelled cells were identified
as dyskaryotic by the Pap counterstain. The MCM test was read more quickly than the Pap test (approximately 2 vs 10min) and there
was 100% inter-observer agreement compared with 85% for Pap (Po0.0001). The MCM test detected 10 biopsy-proven cancers or
pre-cancers that were not detected by Pap (P¼0.002; P¼0.016 excluding three cases where the Pap was deemed unsatisfactory on
review). The cases in question included one recurrent squamous carcinoma and one adenocarcinoma in a screening patient who
would have returned to 5 year recall. There were no false positive MCM test results. We propose that MCM immunocytochemistry
has considerable advantages for cervical screening in developing countries like India.
British Journal of Cancer (2007) 96, 1107–1111. doi:10.1038/sj.bjc.6603679 www.bjcancer.com
Published online 6 March 2007
& 2007 Cancer Research UK
Keywords: cervix; screening; diagnostic accuracy; minichromosome maintenance proteins; immunocytochemistry
                                             
Carcinoma of the uterine cervix is the most common malignancy
in women in India, with over 126000 cases per year (Nandakumar,
1996). More than 80% of these are diagnosed at an advanced stage,
leading to 5 year survival rates of o40% (Shankarnarayanan, 1998;
Dinshaw et al, 1999). The majority of cases represent squamous
cell carcinoma (SCC), although adenocarcinoma and adenosqua-
mous carcinoma are also encountered. Cervical screening in India
is currently restricted to specialist institutes only and is therefore
not available for the vast majority of the population. Widespread
adoption of a practicable screening test could potentially decrease
disease incidence and improve patient survival, as has been
accomplished in developed nations (Baldwin et al, 2003).
For a cervical screening test to be adopted, the combined cost
of performing and reading it must be affordable. The current
Papanicolaou (Pap) test is difficult to assess, particularly for the
conventional smears used in India, where liquid based cytology
(LBC) is not affordable. The Pap test requires skilled operators,
who are expensive to educate and retain in post. This leads either
to the test not being adopted or, at the best, to it being performed
infrequently, rather than regularly as part of a cervical screening
programme. In this context, the widely acknowledged limitations
on sensitivity and specificity of a single Pap test would
substantially limit clinical effectiveness (Baldwin et al, 2003). A
screening test that can be assessed quickly and/or by less highly
trained operators, while remaining effective in detecting disease,
would potentially be affordable in resource-limited countries. We
have tested the value in such a setting of immunocytochemical
staining for minichromosome maintenance (MCM) proteins 2–7,
as biomarkers of abnormal cervical cells.
MCM proteins 2–7 are essential for DNA replication in all
eukaryotic cells and for restricting replication to once per cell cycle
(Kearsey and Labib, 1998; Gonzalez et al, 2005). These proteins,
which are abundant throughout the cell cycle (Kearsey et al, 1996;
Maiorano et al, 1996), are downregulated following cell cycle exit
by quiescence, differentiation or senescence (Musahl et al, 1998;
Madine et al, 2000; Stoeber et al, 2001). In normal cervical
epithelium, MCMs are confined to the basal proliferative
compartment and are absent from terminally differentiated
superficial keratinocytes (Williams et al, 1998; Freeman et al,
1999; Baldwin et al, 2003). In contrast, in pre-malignant cervical
intraepithelial neoplasia (CIN), the cellular proliferative compart-
ment expands in proportion to histological grade, resulting in
MCM-positive cells being present at the epithelial surface. We
demonstrated that such aberrant expression can be exploited to
improve detection of abnormal cells in cervical smears (Williams
et al, 1998) and subsequently showed that the principle can be
extended to early detection of neoplasia at other sites, including
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slarge bowel (Davies et al, 2002), larynx (Chatrath et al, 2003) and
oral cavity (Scott et al, 2006).
In the present study, we have conducted an initial investigation
of the suitability of MCM staining for the detection of abnormal
cells in cervical smear samples from 455 Indian women. Our
objective was to compare the efficacy of immunocytochemistry for
MCMs (using pooled antibodies against MCM2 and MCM5) vs
standard Pap testing, in conditions that apply in typical Indian
cervical screening laboratories. To this end, conventional (i.e. non-
monolayer) slides underwent manual staining and were examined
by a cytotechnician and subsequently by a consultant cytopath-
ologist. Our data will inform the design of appropriately powered
large-scale future studies.
MATERIALS AND METHODS
Smear samples
In a prospective study, samples were obtained from 455 women
who attended the gynaecology clinic at Kidwai Cancer Hospital in
Bangalore, India between January and August 2004 (Figure 1). The
study was approved by the Kidwai Local Research Ethics
Committee (reference: PER/CAB-I/D-I/13/01). The sample popula-
tion included 404 non-selected women who voluntarily attended
for cervical screening examination (available for a small fee in
Kidwai Memorial Cancer Hospital) and 51 consecutive women
undergoing follow-up for treated cervical carcinoma. All subjects
invited to take part in the study agreed to do so. Two samples were
collected from each individual by a specialist gynaecologist, using
a cervical cytobrush (TriPath, Burlington, NC, USA). The tip of the
cytobrush was placed at the cervical os and rotated gently through
3601 three times to obtain each sample. There were no adverse
events in any of the subjects. Smears were prepared by spreading
the samples uniformly across glass slides, which were immediately
cytofixed (Surgipath, Richmond, IL, USA). The first smear was
used for conventional Pap staining, which, as the standard cervical
screening method in India, served as the reference test for the
study. The second smear was used for immunocytochemistry,
employing mouse monoclonal antibodies against human MCM2
and MCM5 (Scott et al, 2006). The tests were performed and
assessed within 24h of each other. Cases were managed clinically
according to test results (see below). Biopsies were taken if
abnormalities suggestive of cervical malignancy or pre-malignancy
were visualised, either at the time of initial specialist examination
or during any subsequent colposcopy.
Immunohistochemistry
Immunostaining was carried out as described previously (Williams
et al, 1998). In brief, smears were soaked in methanol for 5min to
remove cytofix. Cells were then permeabilised with 4mM sodium
deoxycholate for 10min, washed in Tris-buffered saline (TBS)
containing 0.25% Triton X-100, and blocked overnight with 10%
goat serum in TBS. Pooled primary antibodies were diluted in TBS
containing 1% bovine serum albumin (anti-MCM2 at 1:50 and
anti-MCM5 at 1:20) and 200ml was added to each smear. Slides
were incubated overnight at 41C in a humidified chamber on an
orbital shaker, then washed in TBS and incubated for 1h at room
temperature with biotinylated goat anti-mouse secondary antibody
(DAKO, Ely, UK) at 1:200. Following quenching of endogenous
peroxidase activity in 0.6% hydrogen peroxide for 5min, signal
was detected using streptavidin horseradish peroxidase and
diaminobenzidine (both DAKO, Ely, UK). The reaction was
stopped by rinsing in water and slides were counterstained with
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Figure 1 Flow chart summarising study design and results. *For three cases in this group, the Pap smear was deemed unsatisfactory, rather than negative,
on review.
MCM immunocytochemistry for cervical cancer screening
G Mukherjee et al
1108
British Journal of Cancer (2007) 96(7), 1107–1111 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe standard Pap method (to produce an ‘immunoenhanced’ Pap
stain). Negative controls were performed by omitting the primary
antibodies. Tissue sections showing CIN were used as positive
controls (Freeman et al, 1999).
Smear evaluation and statistical analysis
Both the Pap and the MCM stained slides were examined by a
cytotechnician and then by one of two consultant cytopathologists,
who were blinded to the opinion of the cytotechnician, in order to
test inter-observer variation. When assessing the Pap test, the
observers were blinded to the results of the MCM test and vice
versa. All the observers had over 15 years experience in their
respective posts. All available clinical information was provided to
each observer. Any discrepant diagnoses were subsequently
resolved by consensus between all three observers.
The Pap test was reported using ABC2 criteria (Johnson and
Patnick, 2000). The test was regarded as positive if there was a
diagnosis of mild dyskaryosis or worse, as the former is the trigger
point for further clinical intervention in Kidwai Memorial
Hospital. Borderline changes in squamous or glandular cells were
considered to represent negative results. The MCM test was
regarded as positive if there was nuclear staining in epithelial cells
in which features of mild dyskaryosis or worse could be identified
from the Pap counterstain.
Further patient management depended on the results of the
MCM and Pap tests. Cases that were positive by either test were
reviewed and patients underwent colposcopy and biopsy (see
Results section for details). In total, 19 of the 455 patients in the
study underwent biopsy. All biopsies were reported using the CIN
classification by a consultant histopathologist, with over 15 years
experience, who was blinded to the results of the cytological tests.
The results of the MCM test were compared with the findings in
the accompanying Pap smear and with the histopathological
diagnosis in tissue samples (where available). The non-parametric
McNemar’s test (two-sided) was used to determine whether one
test was significantly more sensitive than the other at detecting
cervical malignancy (of any type) and pre-malignancy (CIN of any
grade and cervical glandular intraepithelial neoplasia), as well as to
compare inter-observer variation in assessing the two tests.
RESULTS
Assessing MCM stained cervical smears
The MCM test was evaluated in the setting of a typical Indian
cervical screening laboratory. Manually stained cervical smears
were examined by a cytotechnician and one of two consultant
cytopathologists. In all cases where immunopositive cells were
identified, they were seen readily, even at low magnification
(Figure 2A). The Pap counterstain enabled the features of the
immunopositive cells to be examined by the observers (who, it
should be noted, were experienced in assessing such features)
(Figure 2B). Of the 455 smears examined, 19 were MCM positive
but identified as not showing mild dyskaryosis or worse (therefore
being test negative) by the Pap counterstain.
Importantly, the time taken to read the MCM test slides was
much shorter than for the Pap smears (approximately 2min vs
10min). Moreover, there was 100% agreement between observers
in calling the MCM test in this study. In comparison, the inter-
observer agreement for Pap stained slides was significantly lower
at only 85% (387 of 455 smears) (Po0.0001; n¼455; McNemar’s
Test).
Patients attending for cervical screening
Between January and August 2004, samples were collected from
404 patients aged from 25 to 75 years, who had attended solely for
cervical screening. Of the 404 cases, 388 were MCM negative and
16 were MCM positive. All 388 cases negative for MCM were
reported as either inflammatory or negative in the accompanying
routine Pap smears: no MCM negative case showed an abnormality
by Pap testing. All 16 cases positive for MCM underwent further
examination and biopsy. The findings were as follows:
(a) Three MCM positive cases were initially reported as negative
by Pap smear. On review, it was decided that the quality of
these smears was not satisfactory. This led to repeat smears,
which in all three cases were reported as showing borderline
squamous abnormalities. All three patients then underwent
colposcopy and biopsy, from which two cases were diagnosed
as CIN1 and one as CIN3.
(b) Three MCM positive cases were reported as borderline
squamous abnormalities in the Pap smear. All three patients
underwent colposcopy and biopsy, from which two cases were
diagnosed as CIN1 and one as CIN3.
(c) One case was reported as showing borderline glandular
abnormalities in the Pap smear. The patient was demonstrated
to have adenocarcinoma of the cervix on biopsy.
(d) Two cases showed only necrosis on Pap smear. Both were
confirmed as SCC on biopsy.
(e) Four cases were diagnosed as severe dyskaryosis by Pap smear
and all proved to be SCC on biopsy.
(f) Three cases were diagnosed as showing SCC on Pap smear and
all were confirmed by biopsy.
Patients attending for follow-up of previously diagnosed
cervical carcinoma
Fifty-one patients in the study were under routine follow-up,
having previously received treatment (combinations of surgery/
radiotherapy/chemotherapy) for cervical carcinoma. The patients
were aged between 25 and 75 years. No patient was undergoing
active therapy and none reported symptoms attributable to the
cervix or lower genital tract. Of these samples, 48 were negative by
MCM staining. None of these cases showed an abnormality by Pap
AB
200 m 40 m
Figure 2 (A and B) Representative images of the immunoenhanced Pap test, showing MCM-positive cells at (A) low power and (B) high power.
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as follows:
(a) One patient showed borderline squamous abnormalities on
Pap staining. An indurated area of tissue was seen at
colposcopy, which on biopsy was found to be SCC.
(b) Two patients showed SCC on Pap staining. In both cases, SCC
was confirmed on biopsy.
Comparison of MCM Testing vs Pap Testing
Overall, the combination of MCM staining and Pap counter-
staining enabled the diagnosis of 10 cases of biopsy-proven
cervical malignancy or pre-malignancy that were missed using Pap
staining (P¼0.002; n¼455; McNemar’s Test). Even excluding the
three unsatisfactory Pap smears in the patients attending for
routine screening (group (a) in the cervical screening section
above), seven of the 455 smears examined were false negatives by
Pap staining, with the sensitivity of MCM staining being
significantly superior (P¼0.016; n¼452; McNemar’s Test). There
was no evidence of reduced specificity with the MCM test, which
produced no false positive results. As the patients with Pap
negative, MCM negative smears did not undergo further examina-
tion and biopsy, it was not possible to determine the absolute
sensitivity, specificity and negative predictive value for either test.
The positive predictive value for the MCM test in this initial study
was 100% for CIN1 or worse (19/19 cases) and 79% (15/19 cases)
for CIN3 or worse.
DISCUSSION
The abnormal expression of MCMs in pre-malignant and
malignant lesions of the cervix make them potentially excellent
biomarkers for detecting abnormally proliferating cells (Gonzalez
et al, 2005) and led us to develop a modification of the standard
Pap smear that incorporated MCM immunocytochemistry (the
immunoenhanced Pap test) (Williams et al, 1998). Pap staining,
the traditional method used to detect abnormal cervical epithelial
cells, is subjective and error-prone if conducted in isolation
(Baldwin et al, 2003), as affordable screening would have to be in
developing nations. Pap testing of LBC samples has been approved
as a replacement for the conventional Pap smear and is considered
to be significantly more effective at detecting cervical lesions
(Kirschner et al, 2006). However, LBC is not being used in any of
the major hospitals in India at present, for economic reasons. In
view of the limitations of Pap testing in cervical smears, there
remains a pressing need for alternative tests of greater efficacy. We
therefore examined whether MCM staining would be a superior
method of detecting cervical pre-cancer and cancer in the setting
of a typical Indian screening laboratory, using conventional (non-
monolayer) smears and without the deployment of additional
facilities or technology.
Combined MCM staining and Pap counterstaining detected 10
cases of biopsy-proven cervical cancer or pre-cancer that were
missed using Pap staining. In three of these cases, the Pap smears
were reclassified as inadequate on review and had to be repeated.
Interestingly, the MCM test was adequate for the identification of
abnormal cells in the sample that accompanied the Pap stained
slide in these three cases. As the Pap and MCM test slides were
obtained separately, we cannot exclude that this difference was due
to sampling bias. These cases not withstanding, the sensitivity of
the MCM test was still significantly superior to Pap testing.
Absolute sensitivity values cannot be given for either test as no
tissue diagnosis was made on the Pap negative, MCM negative
cases, for practical and financial reasons. Nevertheless, our
findings have important clinical implications, as several women
whose abnormalities were missed by Pap testing would not have
undergone further investigation based on their Pap test result. The
abnormalities in these women included one case of CIN3 and one
adenocarcinoma in the cervical screening subjects and one SCC in
the follow-up patients. For the screening group, the interval to the
next clinical examination would have been at least 5 years.
The MCM test showed no reduction in specificity in our study,
with no false positive results. It should be noted that the criteria
used to diagnose MCM test positive cases required analysis by a
consultant cytopathologist, assessing both staining results and the
morphology of the immunopositive cells. MCMs can be expressed
in cells showing reactive features (Williams et al, 1998), and
whereas the morphology of reactive cells can generally be
identified by experienced observers, any algorithms that did not
take such information into account would generate reduced
specificity for disease detection.
MCM testing led to a significant decrease in the inter-observer
variation. This is attributable to the fact that all observers are able
to assess the same cells, as they are readily located by virtue of
their immunopositivity. Moreover, MCM testing substantially
decreased the time needed to assess patient samples, an issue that
is of great importance in the developing world due to the shortage
of trained personnel. The MCM staining process would add cost to
the conventional Pap test and require additional manual handling
steps. However, the levels of skill and training required for this
task are not unduly high and would be attainable and affordable.
Such extra investment would be strongly counterbalanced by an
important benefit of MCM testing, namely that test interpretation
is less labour intensive and time consuming for the cytoscreeners
and cytopathologists that are in such short supply. This fact, when
viewed in combination with the improved test performance, argues
that MCM staining may be of greater benefit and cost effectiveness
than the Pap test as a primary screening method, including in
developing countries like India.
An additional consideration is that, in the longer term, the
analysis of MCM-stained slides has considerable potential for
automation. This would further improve test throughput and
would provide an economy of scale that would facilitate affordable
screening in the large populations of developing countries.
However, as such an approach would be best suited to LBC
samples, the clinical and economic benefits of the various
permutations of methods for obtaining and processing samples
would need careful evaluation. It is also the case that the likelihood
of successful adoption of a screening test depends on the
availability of affordable methods to diagnose and treat the target
disease effectively in the screened populations.
In summary, this study confirms that MCM immunocytochem-
istry has great promise as a technique for screening for cervical
cancer and pre-cancer in resource-poor settings, such as India,
using conventional smears stained manually by immunocyto-
chemistry. We now require appropriately powered larger-scale
studies of the suitability of this method for developing nations. In
due course these studies should incorporate cost-benefit analyses.
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